Pathogen inactivation (PI) of platelet concentrates (PCs) reduces the proliferation/replication
of a large range of bacteria, viruses, and parasites as well as residual leucocytes. Pathogen …

The transfusion of platelets is essential for diverse pathological conditions associated with
thrombocytopenia or platelet disorders. To maintain optimal platelet quality and functions …

Amotosalen and ultraviolet A (UVA) photochemical-based pathogen reduction using the
Intercept™ Blood System (IBS) is an effective and established technology for platelet and …

Pathogen inactivation (PI) for platelet concentrates (PC) is a fairly recent development in
transfusion medicine that is intended to decrease infectious disease transmission from the …

Transfusions of platelets are an important cornerstone of medicine; however, recipients may
be subject to risk of adverse events associated with the potential transmission of pathogens …

BACKGROUND Platelet transfusions can induce alloimmunization against HLA antigens.
The use of pathogen‐reduced platelet concentrates (PCs) was suggested to reduce HLA …

BACKGROUND Pathogen reduction treatment using riboflavin and ultraviolet light
illumination (Mirasol) effectively reduces the risk of transfusion‐transmitted infections. This …

Platelet concentrates (PCs) represent a blood transfusion product with a major concern for
safety as their storage temperature (20–24° C) allows bacterial growth, and their maximum …

Blood banks use pathogen inactivation (PI) technologies to increase the safety of platelet
concentrates (PCs). The characteristics of PI-treated PCs slightly differ from those of …

Background Pathogen inactivation (PI) technologies are currently licensed for use with
platelet (PLT) and plasma components. Treatment of whole blood (WB) would be of benefit …